A Bivalent Vaccine Based on a Replication-Incompetent Influenza Virus Protects against Streptococcus pneumoniae and Influenza Virus Infection
暂无分享,去创建一个
H. Katsura | Shinji Watanabe | Y. Kawaoka | T. Horimoto | K. Oishi | K. Iwatsuki-Horimoto | Y. Akeda | Z. Piao
[1] Steven F. Baker,et al. Protection against Lethal Influenza with a Viral Mimic , 2013, Journal of Virology.
[2] H. Katsura,et al. A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine. , 2012, Vaccine.
[3] E. Fodor,et al. Pseudotyped Influenza A Virus as a Vaccine for the Induction of Heterotypic Immunity , 2012, Journal of Virology.
[4] K. Klugman,et al. The future of pneumococcal disease prevention. , 2011, Vaccine.
[5] R. Malley,et al. Next generation pneumococcal vaccines. , 2011, Current opinion in immunology.
[6] M. Chaussee,et al. Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections. , 2011, Vaccine.
[7] T. Randall,et al. Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza Virus , 2011, The Journal of Immunology.
[8] K. Ishii,et al. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice. , 2011, Vaccine.
[9] J. McCullers,et al. Contribution of Vaccine-Induced Immunity toward either the HA or the NA Component of Influenza Viruses Limits Secondary Bacterial Complications , 2010, Journal of Virology.
[10] R. Heyderman,et al. Potential role for mucosally active vaccines against pneumococcal pneumonia , 2010, Trends in microbiology.
[11] D. Mollura,et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. , 2010, Archives of pathology & laboratory medicine.
[12] J. Kaldor,et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[13] G. Palacios,et al. Streptococcus pneumoniae Coinfection Is Correlated with the Severity of H1N1 Pandemic Influenza , 2009, PloS one.
[14] N. Cox,et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .
[15] K. Oishi,et al. Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. , 2009, Vaccine.
[16] C. Ambrose,et al. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza , 2008, Influenza and other respiratory viruses.
[17] Anthony S Fauci,et al. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.
[18] T. Randall,et al. A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1 , 2008, The Journal of Immunology.
[19] Jeffrey N. Weiser,et al. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease , 2008, Nature Reviews Microbiology.
[20] D. Briles,et al. Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. , 2008, Microbial pathogenesis.
[21] E. Miyaji,et al. Optimized Immune Response Elicited by a DNA Vaccine Expressing Pneumococcal Surface Protein A Is Characterized by a Balanced Immunoglobulin G1 (IgG1)/IgG2a Ratio and Proinflammatory Cytokine Production , 2008, Clinical and Vaccine Immunology.
[22] A. Osterhaus,et al. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. , 2007, Current opinion in biotechnology.
[23] M. J. Jedrzejas. Unveiling molecular mechanisms of bacterial surface proteins: Streptococcus pneumoniae as a model organism for structural studies , 2007, Cellular and Molecular Life Sciences.
[24] Gunther Hartmann,et al. 5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.
[25] A. Pichlmair,et al. RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates , 2006, Science.
[26] J. McCullers. Insights into the Interaction between Influenza Virus and Pneumococcus , 2006, Clinical Microbiology Reviews.
[27] R. Medzhitov,et al. Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.
[28] D. Briles,et al. Nasal Colonization with Streptococcus pneumoniae Includes Subpopulations of Surface and Invasive Pneumococci , 2005, Infection and Immunity.
[29] R. Flavell,et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells , 2005, Nature.
[30] Shizuo Akira,et al. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.
[31] R. de Groot,et al. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. , 2004, The Lancet. Infectious diseases.
[32] R. Cox,et al. Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines , 2004, Scandinavian journal of immunology.
[33] D. Briles,et al. Effects of PspA and Antibodies to PspA on Activation and Deposition of Complement on the Pneumococcal Surface , 2004, Infection and Immunity.
[34] Steven Black,et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.
[35] Yoshihiro Kawaoka,et al. Exploitation of Nucleic Acid Packaging Signals To Generate a Novel Influenza Virus-Based Vector Stably Expressing Two Foreign Genes , 2003, Journal of Virology.
[36] D. Briles,et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. , 2003, The Journal of infectious diseases.
[37] R. Dagan,et al. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers , 2003, The Pediatric infectious disease journal.
[38] A. Schuchat,et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.
[39] S. Dowell,et al. Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis , 2000, Pediatrics.
[40] D. Briles,et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. , 2000, Vaccine.
[41] U. Bauer,et al. [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.
[42] Tokiko Watanabe,et al. Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[43] D. Greenberg,et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. , 1996, The Journal of infectious diseases.
[44] K. Martin,et al. Nuclear transport of influenza virus ribonucleoproteins: The viral matrix protein (M1) promotes export and inhibits import , 1991, Cell.
[45] R. Webster,et al. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. , 1982, Virology.